Hamilton Wealth LLC grew its position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 89.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 63,638 shares of the financial services provider’s stock after buying an additional 30,051 shares during the period. iShares Biotechnology ETF accounts for approximately 2.0% of Hamilton Wealth LLC’s investment portfolio, making the stock its 15th largest position. Hamilton Wealth LLC’s holdings in iShares Biotechnology ETF were worth $10,740,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Darwin Wealth Management LLC acquired a new position in iShares Biotechnology ETF in the second quarter valued at approximately $25,000. Basepoint Wealth LLC purchased a new position in iShares Biotechnology ETF in the fourth quarter worth approximately $26,000. Cary Street Partners Financial LLC acquired a new stake in iShares Biotechnology ETF during the fourth quarter worth $29,000. Copia Wealth Management acquired a new stake in iShares Biotechnology ETF during the fourth quarter worth $34,000. Finally, Caitlin John LLC acquired a new stake in iShares Biotechnology ETF during the fourth quarter worth $34,000. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Stock Performance
NASDAQ:IBB opened at $173.64 on Friday. iShares Biotechnology ETF has a 52 week low of $123.61 and a 52 week high of $179.64. The stock’s fifty day moving average is $170.57 and its two-hundred day moving average is $170.64.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Articles
- Five stocks we like better than iShares Biotechnology ETF
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
